Press Release: Fresenius Kabi : CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi (ustekinumab-aauz)

Measures will streamline claims, reimbursement effective April 2025 LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid...